APA (7th ed.) Citation

Gautier-Veyret, E., Chanoine, S., Pluchart, H., Tonini, J., Fonrose, X., Claustre, J., . . . Stanke-Labesque, F. (2017). Posaconazole Tablets Versus Posaconazole Oral Suspension in Lung Transplant Patients: Which Consequences on Immunosuppressive Therapy? Clinical Therapeutics, 39, e3. https://doi.org/10.1016/j.clinthera.2017.05.012

Chicago Style (17th ed.) Citation

Gautier-Veyret, E., S. Chanoine, H. Pluchart, J. Tonini, X. Fonrose, J. Claustre, P. Bedouch, and F. Stanke-Labesque. "Posaconazole Tablets Versus Posaconazole Oral Suspension in Lung Transplant Patients: Which Consequences on Immunosuppressive Therapy?" Clinical Therapeutics 39 (2017): e3. https://doi.org/10.1016/j.clinthera.2017.05.012.

MLA (9th ed.) Citation

Gautier-Veyret, E., et al. "Posaconazole Tablets Versus Posaconazole Oral Suspension in Lung Transplant Patients: Which Consequences on Immunosuppressive Therapy?" Clinical Therapeutics, vol. 39, 2017, p. e3, https://doi.org/10.1016/j.clinthera.2017.05.012.